Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 10, Pages 5176-5190Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00489
Keywords
-
Categories
Funding
- Czech Science Foundation [18-09502S]
- Israel Science Foundation [1611/14]
- Alex Grass Center for Drug Design and Synthesis
Ask authors/readers for more resources
The substitution inert platinum agent [Pt(1S,2S-diamino cyclohexane) (5,6-dimethyl-1,10-ph enanthroline)](2+) (56MeSS, 5) is a potent cytotoxic metallodrug. In contrast to conventional cisplatin or oxaliplatin, the mechanism of action (MoA) of 5 is fundamentally different. However, details of the mechanism by which the 5,6-dimethyl-1,10-phenanthroline ligand contributes to the cytotoxicity of 5 and its derivatives have not been sufficiently clarified so far. Here, we show that 5 and its Pt(IV) derivatives exhibit an intriguing potency in the triple-negative breast cancer cells MDA-MB-231. Moreover, we show that the Pt(IV) derivatives of 5 act by multimodal MoA resulting in the global biological effects, that is, they damage nuclear DNA, reduce the mitochondrial membrane potential, induce the epigenetic processes, and last but not least, the data provide evidence that changes in the organization of cytoskeleton networks are functionally important for 5 and its derivatives, in contrast to clinically used platinum cytostatics, to kill cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available